Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory

Abstract: Talquetamab is a G protein–coupled receptor class C group 5 member D–targeting bispecific T-cell engager approved for patients with relapsed multiple myeloma based on the MonumenTAL-1 trial. In this retrospective study of 68 patients, we evaluated safety and efficacy of talquetamab in a re...

Descrición completa

Detalles Bibliográficos

Principais autores:	Andrew J. Vegel, Bradley T. Loeffler, Jonathan Lochner, Reed Friend, Alma Habib, Marshall McKenna, Jordan Snyder, Kimberly Green, Rachel DiLeo, Gina Patrus, Prerna Mewawalla, Muhammad Umair Mushtaq, Christopher Strouse, Yun Kyoung Ryu Tiger, Nausheen Ahmed, Abdullah M. Khan, Hamza Hashmi, Barry Paul, Shebli Atrash, Al-Ola Abdallah, Hira Shaikh
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2025-06-01
Series:	Blood Immunology & Cellular Therapy
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S3050597625000016
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!